Evidence map›Paper›PMID 25216250›Full record

ArticlePloS one2014

Sheep lung segmental delivery strategy demonstrates adenovirus priming of local lung responses to bacterial LPS and the role of elafin as a response modulator.

Thomas I Brown, David S Collie, Darren J Shaw, Nina M Rzechorzek, Jean-Michel Sallenave

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Thomas I BrownUniversity of Edinburgh, Medical School, Edinburgh, Scotland, United Kingdom; The Roslin Institute and R(D)SVS, The University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Midlothian, United Kingdom.
David S CollieThe Roslin Institute and R(D)SVS, The University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Midlothian, United Kingdom.
Darren J ShawThe Roslin Institute and R(D)SVS, The University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Midlothian, United Kingdom.
Nina M RzechorzekThe Roslin Institute and R(D)SVS, The University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Midlothian, United Kingdom.
Jean-Michel SallenaveUniversity of Edinburgh, Medical School, Edinburgh, Scotland, United Kingdom.
Roslin Institute · GBUniversity of Edinburgh · GB

Funding

Wellcome TrustWellcome Trust 046712
6 · The paper itself

Abstract

Viral lung infections increase susceptibility to subsequent bacterial infection. We questioned whether local lung administration of recombinant adenoviral vectors in the sheep would alter the susceptibility of the lung to subsequent challenge with bacterial lipopolysaccharide (LPS). We further questioned whether local lung expression of elafin, a locally produced alarm anti-LPS/anti-bacterial molecule, would modulate the challenge response. We established that adenoviral vector treatment primed the lung for an enhanced response to bacterial LPS. Whereas this local effect appeared to be independent of the transgene used (Ad-o-elafin or Ad-GFP), Ad-o-elafin treated sheep demonstrated a more profound lymphopenia in response to local lung administration of LPS. The local influence of elafin in modulating the response to LPS was restricted to maintaining neutrophil myeloperoxidase activity, and levels of alveolar macrophage and neutrophil phagocytosis at higher levels post-LPS. Adenoviral vector-bacterial synergism exists in the ovine lung and elafin expression modulates such synergism both locally and systemically.

Indexed as

AdenoviridaeAdenoviridae InfectionsAnimalsElafinGenetic TherapyGenetic VectorsHumansLipopolysaccharidesLungNeutrophilsSheepSheep, DomesticTransgenesElafinLipopolysaccharides

Identifiers

PMID25216250
PMCPMC4162618
OpenAlexW2042277373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.